Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.

Transplant Direct · 2023 · PMC10184979 · PMID 37197016

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

did not reach statistical significanceP = 0.083so close (0.05 < p ≤ 0.1)

There was a trend toward a lower rate of hospitalization among the 24 LTRs who had received tix-cil compared with the 65 LTRs who had not received tix-cil prophylaxis; however, the results did not reach statistical significance (20.8% versus 43.1%, HR, 0.430; 95% CI, 0.165-1.118; P = 0.083).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.